Histone Deacetylase in Chronic Lymphocytic Leukemia

J.C. Wang, Muhammad I. Kafeel, B. Avezbakiyev, C. Chen, Yuhong Sun, C. Rathnasabapathy, Madhumati Kalavar, Zihao He, J. D. Burton, Stephen Lichter

Oncology · 2011 · 92 citations · 16 references

Abstract

These results suggest: (1) in CLL, elevated HDAC isoenzyme activity is not restricted to one class, and therefore, HDACi therapy may need to be directed to more than one specific class of HDAC; (2) higher HDAC expression activity may indicate a poor prognosis and more advanced disease stage (through indirect evidence), since higher values were found in patients with ZAP-70+ and higher CD44 expression levels.

References

16